The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.
As per the findings of the research, most of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route.
MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of their drug candidates in chronic obstructive pulmonary disease. The technology is used for the in vitro generation of highly specific and fully human antibodies.
The research found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. collaborated with AstraZeneca plc, had given the exclusive rights to AstraZeneca plc for benralizumab in Asia.
Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation and others.
News Courtesy : P&S Market Research